» Articles » PMID: 19100689

Head and Neck Cancer in the Elderly: an Overview on the Treatment Modalities

Overview
Publisher Elsevier
Specialty Oncology
Date 2008 Dec 23
PMID 19100689
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

The percentage of elderly people with head and neck cancers (HNC) is rising due to increasing average lifespan. As with younger patients, elderly patients require a multidisciplinary approach in order to optimise treatment results. The biological, not the chronological, age should be defined individually based on co-morbidities and performance status. A comprehensive geriatric assessment represents the first and essential step for selecting further treatment options. Major improvements have been accomplished in surgical techniques and radiotherapy delivery. Several chemotherapeutic agents and targeted therapies with different toxicity profile are also available. However, the randomised studies that defined the nature of these improvements included only a small proportion of patients older than 65 years. In deciding which treatment strategy would be suitable for an individual elderly patient, we review the literature regarding surgery, radiotherapy, and chemotherapy or their various combinations.

Citing Articles

Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group.

Yasuda K, Kiyota N, Matsuura K, Saito S, Honma Y, Imamura Y Front Oncol. 2025; 14():1441056.

PMID: 39845314 PMC: 11750991. DOI: 10.3389/fonc.2024.1441056.


Frailty and Overall Survival of Older Patients Undergoing Radiotherapy for Head and Neck Cancer: A Prospective Analysis.

Giannotti C, Ottaviani S, Muzyka M, Tagliafico L, Bacigalupo A, Belgioia L Cancers (Basel). 2024; 16(23).

PMID: 39682127 PMC: 11639954. DOI: 10.3390/cancers16233939.


Laryngectomy in Elderly Patients: A Case Series and Review of the Literature.

Ozbek L, Lion P, Patel A, Hughes J, Shah K, Stimpson P Cureus. 2024; 15(11):e49294.

PMID: 38957195 PMC: 11218606. DOI: 10.7759/cureus.49294.


Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges.

Liu J, Chao T, Liu Y, Gong C, Zhang Y, Xiong H Pharmaceutics. 2023; 15(6).

PMID: 37376154 PMC: 10305175. DOI: 10.3390/pharmaceutics15061706.


Cancer treatment-induced NAD+ depletion in premature senescence and late cardiovascular complications.

Banerjee P, Olmsted-Davis E, Deswal A, Nguyen M, Koutroumpakis E, Palaskas N J Cardiovasc Aging. 2022; 2.

PMID: 35801078 PMC: 9258520. DOI: 10.20517/jca.2022.13.